99 related articles for article (PubMed ID: 18058997)
1. Clinical application of deferasirox: practical patient management.
Vichinsky E
Am J Hematol; 2008 May; 83(5):398-402. PubMed ID: 18058997
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Gattermann N; Jarisch A; Schlag R; Blumenstengel K; Goebeler M; Groschek M; Losem C; Procaccianti M; Junkes A; Leismann O; Germing U
Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
[TBL] [Abstract][Full Text] [Related]
3. Iron-chelating therapy for transfusional iron overload.
Brittenham GM
N Engl J Med; 2011 Jan; 364(2):146-56. PubMed ID: 21226580
[TBL] [Abstract][Full Text] [Related]
4. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
Vallejo C; Batlle M; Vázquez L; Solano C; Sampol A; Duarte R; Hernández D; López J; Rovira M; Jiménez S; Valcárcel D; Belloch V; Jiménez M; Jarque I;
Haematologica; 2014 Oct; 99(10):1632-7. PubMed ID: 24997153
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox: appraisal of safety and efficacy in long-term therapy.
Chaudhary P; Pullarkat V
J Blood Med; 2013; 4():101-10. PubMed ID: 23966805
[TBL] [Abstract][Full Text] [Related]
6. Update on the use of deferasirox in the management of iron overload.
Taher A; Cappellini MD
Ther Clin Risk Manag; 2009; 5():857-68. PubMed ID: 19898650
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Study of Multifunctional Cyclodextrin-Deferasirox Hybrids.
Gascon JM; Oliveri V; McGown A; Kaya E; Chen YL; Austin C; Walker M; Platt FM; Vecchio G; Spencer J
ChemMedChem; 2019 Aug; 14(16):1484-1492. PubMed ID: 31162826
[TBL] [Abstract][Full Text] [Related]
8. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).
Pennell DJ; Porter JB; Piga A; Lai Y; El-Beshlawy A; Belhoul KM; Elalfy M; Yesilipek A; Kilinç Y; Lawniczek T; Habr D; Weisskopf M; Zhang Y; Aydinok Y;
Blood; 2014 Mar; 123(10):1447-54. PubMed ID: 24385534
[TBL] [Abstract][Full Text] [Related]
9. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Taher AT; Origa R; Perrotta S; Kourakli A; Ruffo GB; Kattamis A; Goh AS; Cortoos A; Huang V; Weill M; Merino Herranz R; Porter JB
Am J Hematol; 2017 May; 92(5):420-428. PubMed ID: 28142202
[TBL] [Abstract][Full Text] [Related]
10. Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
Huang WF; Chou HC; Tsai YW; Hsiao FY
Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1176-82. PubMed ID: 24946110
[TBL] [Abstract][Full Text] [Related]
11. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
Taher AT; Wali Y; Cruz MC; Charoenkwan P; Aydinok Y; Werner O; Govindaraju S; Romen F; Viprakasit V
Haematologica; 2024 May; 109(5):1413-1425. PubMed ID: 37855069
[TBL] [Abstract][Full Text] [Related]
12. Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread.
Dogra S; Arora A; Aggarwal A; Passi G; Sharma A; Singh G; Barnwal RP
Front Microbiol; 2021; 12():794176. PubMed ID: 35058909
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Iron Chelation and Gallium-Based Therapies for Antibiotic Resistant Bacterial Infections.
Vinuesa V; McConnell MJ
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809032
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Subclinical Renal Glomerular and Tubular Dysfunction in Children with Beta Thalassemia Major.
Mahmoud AA; Elian DM; Abd El Hady NM; Abdallah HM; Abdelsattar S; Khalil FO; Abd El Naby SA
Children (Basel); 2021 Feb; 8(2):. PubMed ID: 33546213
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Murray C; De Gelder T; Pringle N; Johnson JC; Doherty M
Can Oncol Nurs J; 2016; 26(1):29-39. PubMed ID: 31148744
[TBL] [Abstract][Full Text] [Related]
16. Management of iron overload in the Canadian hematology/oncology population: Implications for nursing practice.
Murray C; De Gelder T; Pringle N; Johnson JC; Doherty M
Can Oncol Nurs J; 2016; 26(1):19-28. PubMed ID: 31148725
[TBL] [Abstract][Full Text] [Related]
17. Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect.
Ambrose PG; VanScoy BD; Luna BM; Yan J; Ulhaq A; Nielsen TB; Rudin S; Hujer K; Bonomo RA; Actis L; Skaar E; Spellberg B
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782989
[TBL] [Abstract][Full Text] [Related]
18. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Patnaik MM; Tefferi A
Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
Taher AT; Origa R; Perrotta S; Kouraklis A; Ruffo GB; Kattamis A; Goh AS; Huang V; Zia A; Herranz RM; Porter JB
Health Qual Life Outcomes; 2018 Nov; 16(1):216. PubMed ID: 30453981
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
